The research team performed a literature search on MEDLINE and EMBASE, from their inception through May 2017. They included studies that reported odds ratios or relative risks comparing the risk of developing CDI and/or the clinical outcomes of CDI in patients who received statins treatment versus those who did not receive statins.
They examined 10 observational studies that included 37,109 patients.
Researchers found statins reduced the risk of CDI development compared to no treatment. However, among patients who developed CDI, the use of statins did not significantly reduce risk of recurrent CDI. The research also did not show a link between statins use and reduced CDI severity, when compared to no use of statins.
More articles on healthcare quality:
CDC: Influenza activity low at start of flu season
Gov. Jerry Brown declares state of emergency over California’s hep A outbreak
Top 10 infection control stories, Oct. 9-13
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.